Explore Oro Lesion, OrisDX's saliva-based molecular diagnostic adjunct for earlier oral-cancer assessment in routine dental settings.

• Simple 10 second swish and swirl for sample collection
• Detects somatic mutations associated with oral cavity squamous cell carcinoma.
• Genomic results delivered securely to providers within days to guide triage and referral.

Discuss implementation, clinical workflow integration, and partnership opportunities with OrisDX for dental and clinical practice settings.

• Scalable diagnostic protocols designed for multi-clinic and DSO deployment.
• No cost to the clinic for the Oro Lesion test, supporting accessible adoption.
• Reimbursement guidance and administrative support for clinical staff.

Review the science, clinical validation, peer-reviewed publications, and molecular rationale underpinning the Oro Lesion platform.

• Next-generation sequencing and saliva-based multiomic testing infrastructure.
• Clinical evidence supporting earlier detection of head and neck squamous cell carcinoma.
• Proprietary genomic analysis identifying cancer-causing mutations and molecular biomarkers.

Access educational resources on oral cancer risk factors, early detection, and the molecular science behind salivary diagnostics.

• Informational content on oral cavity squamous cell carcinoma and known risk factors.
• Guidance on recognizing indeterminate oral lesions and pursuing clinical evaluation.
• Resources for patients, clinicians, and caregivers navigating the care pathway.

Learn about OrisDX's mission to advance earlier oral-cancer detection through molecular diagnostics and patient-first clinical navigation.

• Company background, leadership, and scientific advisory expertise.
• Our commitment to bridging the gap between dental and medical care.
• The clinical and human imperative driving proactive, early action in oral oncology.